| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3292661 | Gastroenterology | 2014 | 16 Pages |
Abstract
A higher percentage of patients with chronic HCV infection who received immunotherapy with TG4040 followed by TG4040 and PEG-IFNα/RBV achieved a cEVR compared with patients who received only PEG-IFNα/RBV therapy. These findings show that immunotherapies that activate T cells are effective in patients with chronic HCV infection. ClinicalTrials.gov number, NCT01055821.
Keywords
RBVPEG-IFNαcEVRSVR24SAEELISPOTETRPBMCSVRITTLOD یا Limit of detectionRibavirinPeripheral blood mononuclear celladverse eventSerious adverse eventIntent-to-treatMVAlimit of detectionHCVHepatitis C virusVaccineModified vaccinia AnkaraSustained virologic responseImmune responseend of treatmentcomplete early virologic response
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Adrian M. Di Bisceglie, Ewa Janczweska-Kazek, François Habersetzer, Wlodzimierz Mazur, Carol Stanciu, Vicente Carreno, Coman Tanasescu, Robert Flisiak, Manuel Romero-Gomez, Alexander Fich, Vincent Bataille, Myew-Ling Toh, Marie Hennequi,